hero

Join Us

Discover available job opportunities within our portfolio
Powered by Getro
Showing 40 companies
Abridge
Abridge
16 jobs
Data and Analytics
DeepTech
Health
Software
11 - 50

Abridge is a medical conversation AI startup that offers an audio-based system to record and summarize medical conversations. It was created for everyone, with a mission to help better understand their health conversations, whether at home or in the hospital.

Andes
Andes
1 jobs
Agriculture and Farming
Biotechnology
DeepTech
Sustainability
51 - 200
Series A

Andes empowers microbes to enable positive action against climate change.

Biotechnology
Consumer Products
DeepTech
Health
11 - 50
Series B

Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Data and Analytics
DeepTech
Health
Software
11 - 50

Braid Health is a digital health innovation company that develops an AI-powered diagnostic collaboration platform that improves the speed, quality, and workflow of radiologists and healthcare providers. Braid Health empowers radiologists and healthcare providers to deliver diagnoses for any patient, anywhere.

Biotechnology
DeepTech
Health
11 - 50
Series A

Character Biosciences (formerly Clover Therapeutics) is a precision medicine platform that is unlocking the patterns of age-related diseases in people of diverse backgrounds. Our mission is to use human genetics to understand what drives diseases so we can discover targeted therapies to more effectively treat patients - many of whom lack any treatment options today. Character partners with patients, providers, payers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research. Our approach integrates genomics, longitudinal clinical and imaging data, machine learning, and novel experimental approaches to identify the molecular drivers of disease progression and develop innovative targeted medicines.

Biotechnology
DeepTech
Manufacturing
51 - 200
Series C+

Checkerspot is a materials innovation company. Advances in our understanding of biology, chemistry and materials science are converging with breakthroughs in data science and unleashing capabilities they once only imagined. Checkerspot's technology unlocks this potential, expands the palette of materials available to product designers and enables a more intentional way to design performance materials for specific applications. As a graduate of the Illumina Accelerator program, we are building a technology platform that enables the design – at a molecular level – of new materials. Through applications development, they prototype and iterate on specific product embodiments. By engaging directly with product users and partnering with socially responsible corporations, they design and bring to market superior products with better materials.

We are a collective of innovators, researchers, and scientists committed to revolutionizing the gene therapy industry. Our naming inspiration stems from the iconic national flower of Scotland, Cirsium Vulgare, and the tenacious California Thistle, Cirsium Occidentale. Much like these resilient plants, we embody qualities of tenacity, passion, disruption, and adaptability, thriving even in the most formidable of conditions. This dedication fuels our mission to improve global access to life-saving gene therapies for patients in need.

Lending and Investments
11 - 50

Curie.Bio is a founder-focused seed-stage venture firm combined with an industry-grade therapeutics accelerator focused on one thing: helping entrepreneurial founders launch viable therapeutics companies. Curie.Bio does this by giving founders access to a team of the world’s best drug hunters and drug makers, seed capital, and best-of-breed services - everything a founder needs to get from concept to a compelling quality dataset that enables an awesome Series A financing. In a nutshell, we want founders in control of their own company and focused on their area of expertise and creativity, while we help make the rest happen smoothly.

DeepTech
Manufacturing
1 - 10

Cypris Materials is developing a new generation of sustainable color that broadens the color gamut while simplifying manufacturing, application and formulation. Cypris Materials, Inc. has harnessed the transformative power of structural color - a method of producing color that has evolved over millions of years. Cypris Materials' structural coating platform helps industry-leading companies and individuals redefine the capabilities of color. Our polymers, backed by an extensive patent portfolio, unlock exclusive colors and effects that can only be achieved through our paint. Cypris’ materials enable a new paradigm: the first safe and sustainable structural color palette, free of toxic pigments and dyes.

Biotechnology
Consumer Products
DeepTech
Health
51 - 200
Series B

Debut Biotech is a biotechnology company that focuses on providing specialty enzyme solutions combined with continuous manufacturing. It combines the power of enzymes with continuous manufacturing to create and modify small and large molecules for a wide range of industries and applications. The company was founded in 2019 and is based in San Diego, California.

Biotechnology
DeepTech
Health
Manufacturing
11 - 50
Series A

Dimension Inx focuses on creating advanced biomaterials and 3D-printed implants that fundamentally change human disease and debilitation. It specializes in the fields of additive manufacturing, 3D-printing, biomaterials, and manufacturing. It was founded in 2017 and headquartered in Chicago, Illinois.

Biotechnology
Data and Analytics
DeepTech
Health
Software
51 - 200
Series A

Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.